Abbott Wins FDA Approval for CardioMEMS HERO, Gains CE Mark for TactiFlex Duo
Abbott’s CardioMEMS HERO pulmonary artery pressure reader received FDA approval, featuring new design enhancements to deliver daily heart failure insights for patients and clinicians. The company also secured CE Mark in Europe for its TactiFlex Duo Sensor Enabled ablation catheter, expanding its pulsed field atrial fibrillation treatment portfolio.
1. CardioMEMS HERO FDA Approval
Abbott’s CardioMEMS HERO pulmonary artery pressure reader received FDA approval, introducing new design features that deliver daily hemodynamic insights. This device empowers heart failure patients and clinicians to monitor pulmonary artery pressure remotely, aiming to detect early decompensation and reduce hospital admissions.
2. TactiFlex Duo CE Mark in Europe
The TactiFlex Duo Ablation Catheter, Sensor Enabled, secured CE Mark in Europe, marking Abbott’s latest advancement in pulsed field ablation technology for atrial fibrillation. Its integrated sensor feedback offers precise lesion assessment and streamlined workflow, supporting safer and more efficient ablation procedures.
3. Market and Financial Implications
These regulatory wins bolster Abbott’s cardiovascular device portfolio, enabling entry into high-growth segments of remote heart failure monitoring and advanced AF therapy. Expanded product offerings are expected to diversify revenue streams and support margin expansion as adoption scales across key markets.